Regimens for Cirrhotic Patients

Paul Y. Kwo

Research output: Contribution to journalArticle

Abstract

Therapy for hepatitis C has entered the era of all-oral direct-acting antiviral agents. Sustained response rates are now greater than 90% for all genotypes, although patients with cirrhosis remain the most difficult to treat. There are limited data for patients with cirrhosis and with hepatitis C genotypes 4 and 6 with cirrhosis. Genotype 3 patients with cirrhosis need additional strategies to achieve the sustained virologic response rates seen in genotype 1 patients with cirrhosis. This article outlines the currently available therapies for patients with cirrhosis and hepatitis C across all genotypes, with suggested management strategies.

Original languageEnglish (US)
Pages (from-to)657-667
Number of pages11
JournalClinics in Liver Disease
Volume19
Issue number4
DOIs
StatePublished - Nov 1 2015

Fingerprint

Fibrosis
Genotype
Hepatitis C
Antiviral Agents
Therapeutics

Keywords

  • Cirrhosis
  • Direct-acting antivirals
  • Hepatitis C
  • Ledipasvir
  • Ombitasvir
  • Paritaprevir
  • Simeprevir
  • Sofosbuvir

ASJC Scopus subject areas

  • Hepatology

Cite this

Regimens for Cirrhotic Patients. / Kwo, Paul Y.

In: Clinics in Liver Disease, Vol. 19, No. 4, 01.11.2015, p. 657-667.

Research output: Contribution to journalArticle

Kwo, Paul Y. / Regimens for Cirrhotic Patients. In: Clinics in Liver Disease. 2015 ; Vol. 19, No. 4. pp. 657-667.
@article{0ce7e9a20b6d426d8791c25be292caf1,
title = "Regimens for Cirrhotic Patients",
abstract = "Therapy for hepatitis C has entered the era of all-oral direct-acting antiviral agents. Sustained response rates are now greater than 90{\%} for all genotypes, although patients with cirrhosis remain the most difficult to treat. There are limited data for patients with cirrhosis and with hepatitis C genotypes 4 and 6 with cirrhosis. Genotype 3 patients with cirrhosis need additional strategies to achieve the sustained virologic response rates seen in genotype 1 patients with cirrhosis. This article outlines the currently available therapies for patients with cirrhosis and hepatitis C across all genotypes, with suggested management strategies.",
keywords = "Cirrhosis, Direct-acting antivirals, Hepatitis C, Ledipasvir, Ombitasvir, Paritaprevir, Simeprevir, Sofosbuvir",
author = "Kwo, {Paul Y.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.cld.2015.06.006",
language = "English (US)",
volume = "19",
pages = "657--667",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Regimens for Cirrhotic Patients

AU - Kwo, Paul Y.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Therapy for hepatitis C has entered the era of all-oral direct-acting antiviral agents. Sustained response rates are now greater than 90% for all genotypes, although patients with cirrhosis remain the most difficult to treat. There are limited data for patients with cirrhosis and with hepatitis C genotypes 4 and 6 with cirrhosis. Genotype 3 patients with cirrhosis need additional strategies to achieve the sustained virologic response rates seen in genotype 1 patients with cirrhosis. This article outlines the currently available therapies for patients with cirrhosis and hepatitis C across all genotypes, with suggested management strategies.

AB - Therapy for hepatitis C has entered the era of all-oral direct-acting antiviral agents. Sustained response rates are now greater than 90% for all genotypes, although patients with cirrhosis remain the most difficult to treat. There are limited data for patients with cirrhosis and with hepatitis C genotypes 4 and 6 with cirrhosis. Genotype 3 patients with cirrhosis need additional strategies to achieve the sustained virologic response rates seen in genotype 1 patients with cirrhosis. This article outlines the currently available therapies for patients with cirrhosis and hepatitis C across all genotypes, with suggested management strategies.

KW - Cirrhosis

KW - Direct-acting antivirals

KW - Hepatitis C

KW - Ledipasvir

KW - Ombitasvir

KW - Paritaprevir

KW - Simeprevir

KW - Sofosbuvir

UR - http://www.scopus.com/inward/record.url?scp=84943583058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943583058&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2015.06.006

DO - 10.1016/j.cld.2015.06.006

M3 - Article

C2 - 26466654

AN - SCOPUS:84943583058

VL - 19

SP - 657

EP - 667

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 4

ER -